Company intelligence / Profile preview

Phagenesis

Manchester, United Kingdomphagenesis.com ↗

Ownership: Private
Development stage: Commercial

Overview

The Phagenyx system has demonstrated significant reductions in hospital length of stay for patients with neurogenic dysphagia, with robust evidence from randomized controlled trials and real-world data. Clinical studies show improved recovery rates and reduced complications such as pneumonia. The system received FDA approval for the US market in 2024.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (Pharyngeal Electrical Stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Phagenyx

Commercial

Indications: Dysphagia, Neurogenic dysphagia

Beyond the preview

Go deeper on Phagenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phagenesis.

Explore the full profile